유전자 편집 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 기술별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)
Gene Editing Market Size, Share & Trends Analysis Report By Product & Service, By Technology, By End-user, By Region, And Segment Forecasts, 2026 - 2033
상품코드
:
1941760
리서치사
:
Grand View Research
발행일
:
2026년 01월
페이지 정보
:
영문 120 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
샘플 요청 목록에 추가
유전자 편집 시장 요약
세계의 유전자 편집 시장 규모는 2025년에 58억 7,000만 달러로 추정되며, 2033년까지 185억 5,000만 달러에 달할 것으로 예측됩니다.
2026년부터 2033년까지 CAGR 15.71%로 성장할 것으로 예상됩니다. 이러한 성장은 첨단 유전자 치료의 도입 확대, 바이오의약품 연구에 대한 투자 증가, 정밀의료에 대한 수요 증가에 힘입은 바 큽니다.
치료용 유전자 치료에 대한 수요 확대
희귀질환 및 유전성 질환에 대한 정밀의료의 필요성이 증가하고 있는 것이 유전자 편집 시장을 견인하는 주요 요인 중 하나입니다. 의료 시스템이 증상 치료에서 보다 표적화된 근본 원인에 대한 개입으로 전환하는 경향이 강해지고 있기 때문입니다. 많은 희귀질환은 단일 유전자 질환이기 때문에 결함 유전자를 직접 수정, 비활성화, 대체할 수 있는 유전자 편집 기술이 적용될 수 있습니다. 기존의 만성질환 치료는 효과에 한계가 있는 약물을 평생 투여하는 경우가 일반적입니다. 그러나 유전자 편집 기술은 단 한 번 또는 극소수의 개입으로 지속적인 효과를 얻을 수 있는 가능성을 열어줍니다.
개발자에게는 기본적인 편집 도구 이상의 것이 필요합니다. 고급 편집 효소를 이용한 돌연변이 특이적 프로그램 실행, 가이드 RNA 설계, 전달 최적화, 그리고 확고한 분석적 검증이 필요합니다. 그 결과, 유전자 편집 시약, GMP 등급 구성요소, 전문 위탁 연구 및 제조 서비스에 대한 지속적인 수요가 발생하고 있습니다. 이러한 요인들, 즉 미충족 수요, 정밀의료 전략, 확장 가능한 플랫폼 개발이 결합되어 유전자 편집 기술은 차세대 치료 혁신의 중요한 성장 동력이 되고 있습니다.
목차 제1장 조사 방법과 범위
제2장 주요 요약
제3장 유전자 편집 시장 변수, 동향 및 범위
제4장 유전자 편집 시장 : 제품 및 서비스별 추정·동향 분석
제5장 유전자 편집 시장 : 기술별 추정·동향 분석
제6장 유전자 편집 시장 : 최종사용자별 추정·동향 분석
제7장 유전자 편집 시장 : 지역별 추정·동향 분석
제8장 세계의 경쟁 구도
제9장 북미의 경쟁 구도
제10장 유럽의 경쟁 구도
제11장 아시아태평양의 경쟁 구도
KSM
영문 목차
Gene Editing Market Summary
The global gene editing market size was estimated at USD 5.87 billion in 2025 and is projected to reach USD 18.55 billion by 2033, growing at a CAGR of 15.71% from 2026 to 2033. This growth is supported by rising adoption of advanced gene therapies, increasing investments in biopharmaceutical research, and growing demand for precision medicine.
Growing demand for curative genetic therapies
The increasing need for precision medicine in rare and genetic disorders is one of the main factors driving the gene editing market, as health care systems are increasingly inclined to shift from symptomatic management to more targeted, root-cause interventions. Many rare diseases are monogenic, making them appropriate candidates for gene-editing techniques that can directly fix, silence, or alter the defective genes. The customary chronic treatment approaches often entail lifelong prescription of medicines with limited effect. However, gene editing opens the door to either single or very rare interventions with lasting results.
The developers need much more than basic editing tools. They need to perform mutation-specific programs with advanced editing enzymes, guide RNA design, delivery optimization, and robust analytical validation. As a result, there has been a continuous demand for gene-editing reagents, GMP-grade components, and specialized contract research and manufacturing services. The combination of the above factors, namely unmet clinical need, precision-focused healthcare strategies, and scalable platform development, has made gene editing a critical growth engine in the next generation of therapeutic innovations.
Global Gene Editing Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global gene editing market report based on product & service, technology, end-user, and region:
Product & Service Outlook (Revenue, USD Billion, 2021 - 2033)
Reagents and Consumables
Software and Systems
Services
Technology Outlook (Revenue, USD Billion, 2021 - 2033)
CRISPR-Cas System
Transcription Activator-Like Effector Nucleases (TALENs)
Zinc Finger Nucleases (ZFNs)
Meganucleases/Homing Endonucleases
End-user Outlook (Revenue, USD Billion, 2021 - 2033)
Biotechnology and Pharmaceutical Companies
University and Research Institutes
Other End-users
Regional Outlook (Revenue, USD Billion, 2021 - 2033)
North America
Europe
Germany
UK
France
Spain
Italy
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
Table of Contents Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product & Service
1.2.2. Technology
1.2.3. End User
1.3. Research Methodology
1.4. Information Procurement
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Gene Editing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing Demand For Curative Genetic Therapies
3.2.1.2. Expansion Of Enabling Ecosystem
3.2.2. Market Restraint Analysis
3.2.2.1. Capital-Intensive Development Pathways
3.2.2.2. Fragmented Regulatory Landscape
3.2.3. Market Opportunity Analysis
3.2.3.1. Monetization Beyond Therapeutic Products
3.2.3.2. Broadening Application Spectrum
3.2.4. Market Challenge Analysis
3.2.4.1. Limitations In Targeted In Vivo Delivery
3.2.4.2. Complex Intellectual Property Environment
3.2.5. Key Partnerships & Collaborations
3.2.6. Patent Analysis
3.2.7. Funding & Investment Landscape
3.3. Industry Analysis Tools
3.3.1. SWOT Analysis
3.3.2. PESTEL Analysis
3.3.3. Porter's Analysis
Chapter 4. Gene Editing Market: Product & Service Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Product & Service Market Share, 2025 & 2033
4.3. Reagents and Consumables
4.3.1. Reagents and Consumables Market Estimates and Forecasts 2021 to 2033 (USD million)
4.4. Software and Systems
4.4.1. Software and Systems Market Estimates and Forecasts 2021 to 2033 (USD million)
4.5. Services
4.5.1. Services Market Estimates and Forecasts 2021 to 2033 (USD million)
Chapter 5. Gene Editing Market: Technology Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Technology Market Share, 2025 & 2033
5.3. CRISPR-Cas System
5.3.1. CRISPR-Cas System Market Estimates and Forecasts 2021 to 2033 (USD million)
5.4. Transcription Activator-Like Effector Nucleases (TALENs)
5.4.1. Transcription Activator-Like Effector Nucleases (TALENs) Market Estimates and Forecasts 2021 to 2033 (USD million)
5.5. Zinc Finger Nucleases (ZFNs)
5.5.1. Zinc Finger Nucleases (ZFNs) Market Estimates and Forecasts 2021 to 2033 (USD million)
5.6. Meganucleases/Homing Endonucleases
5.6.1. Meganucleases/Homing Endonucleases Market Estimates and Forecasts 2021 to 2033 (USD million)
5.7. Technology Landscape and Competitive Insights
Chapter 6. Gene Editing Market: End User Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. End User Market Share, 2025 & 2033
6.3. Biotechnology and Pharmaceutical Companies
6.3.1. Biotechnology and Pharmaceutical Companies Market Estimates and Forecasts 2021 to 2033 (USD million)
6.4. University and Research Institutes
6.4.1. University and Research Institutes Market Estimates and Forecasts 2021 to 2033 (USD million)
6.5. Other End Users
6.5.1. Other End Users Market Estimates and Forecasts 2021 to 2033 (USD million)
Chapter 7. Gene Editing Market: Regional Estimates & Trend Analysis
7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2025 & 2033
7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
7.4.1. U.S.
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework
7.4.1.3. Reimbursement environment
7.4.1.4. Growth drivers
7.4.1.5. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
7.4.2. Canada
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework
7.4.2.3. Reimbursement environment
7.4.2.4. Growth drivers
7.4.2.5. Canada market estimates and forecasts 2021 to 2033 (USD Million)
7.4.3. Mexico
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework
7.4.3.3. Reimbursement environment
7.4.3.4. Growth drivers
7.4.3.5. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
7.5. Europe
7.5.1. UK
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework
7.5.1.3. Reimbursement environment
7.5.1.4. Growth drivers
7.5.1.5. UK market estimates and forecasts 2021 to 2033 (USD Million)
7.5.2. Germany
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework
7.5.2.3. Reimbursement environment
7.5.2.4. Growth drivers
7.5.2.5. Germany market estimates and forecasts 2021 to 2033 (USD Million)
7.5.3. France
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework
7.5.3.3. Reimbursement environment
7.5.3.4. Growth drivers
7.5.3.5. France market estimates and forecasts 2021 to 2033 (USD Million)
7.5.4. Italy
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework
7.5.4.3. Reimbursement environment
7.5.4.4. Growth drivers
7.5.4.5. Italy market estimates and forecasts 2021 to 2033 (USD Million)
7.5.5. Spain
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework
7.5.5.3. Reimbursement environment
7.5.5.4. Growth drivers
7.5.5.5. Spain market estimates and forecasts 2021 to 2033 (USD Million)
7.5.6. Norway
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework
7.5.6.3. Reimbursement environment
7.5.6.4. Growth drivers
7.5.6.5. Norway market estimates and forecasts 2021 to 2033 (USD Million)
7.5.7. Sweden
7.5.7.1. Key country dynamics
7.5.7.2. Regulatory framework
7.5.7.3. Reimbursement environment
7.5.7.4. Growth drivers
7.5.7.5. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
7.5.8. Denmark
7.5.8.1. Key country dynamics
7.5.8.2. Regulatory framework
7.5.8.3. Reimbursement environment
7.5.8.4. Growth drivers
7.5.8.5. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Asia Pacific
7.6.1. Japan
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework
7.6.1.3. Reimbursement environment
7.6.1.4. Growth drivers
7.6.1.5. Japan market estimates and forecasts 2021 to 2033 (USD Million)
7.6.2. China
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework
7.6.2.3. Reimbursement environment
7.6.2.4. Growth drivers
7.6.2.5. China market estimates and forecasts 2021 to 2033 (USD Million)
7.6.3. India
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework
7.6.3.3. Reimbursement environment
7.6.3.4. Growth drivers
7.6.3.5. India market estimates and forecasts 2021 to 2033 (USD Million)
7.6.4. Australia
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework
7.6.4.3. Reimbursement environment
7.6.4.4. Growth drivers
7.6.4.5. Australia market estimates and forecasts 2021 to 2033 (USD Million)
7.6.5. South Korea
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework
7.6.5.3. Reimbursement environment
7.6.5.4. Growth drivers
7.6.5.5. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
7.6.6. Thailand
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework
7.6.6.3. Reimbursement environment
7.6.6.4. Growth drivers
7.6.6.5. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
7.7. Latin America
7.7.1. Brazil
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework
7.7.1.3. Reimbursement environment
7.7.1.4. Growth drivers
7.7.1.5. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
7.7.2. Argentina
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework
7.7.2.3. Reimbursement environment
7.7.2.4. Growth drivers
7.7.2.5. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
7.8. MEA
7.8.1. South Africa
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework
7.8.1.3. Reimbursement environment
7.8.1.4. Growth drivers
7.8.1.5. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
7.8.2. Saudi Arabia
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework
7.8.2.3. Reimbursement environment
7.8.2.4. Growth drivers
7.8.2.5. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
7.8.3. UAE
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework
7.8.3.3. Reimbursement environment
7.8.3.4. Growth drivers
7.8.3.5. UAE market estimates and forecasts 2021 to 2033 (USD Million)
7.8.4. Kuwait
7.8.4.1. Key country dynamics
7.8.4.2. Regulatory framework
7.8.4.3. Reimbursement environment
7.8.4.4. Growth drivers
7.8.4.5. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Global Competitive Landscape
8.1. Global Market Position Analysis, 2025
Chapter 9. North America Competitive Landscape
9.1. Company Profiles
9.1.1. Thermo Fisher Scientific Inc.
9.1.1.1. Company overview
9.1.1.2. Financial performance
9.1.1.3. Product benchmarking
9.1.1.4. Strategic initiatives
9.1.2. Revvity
9.1.2.1. Company overview
9.1.2.2. Financial performance
9.1.2.3. Product benchmarking
9.1.2.4. Strategic initiatives
9.1.3. Danaher
9.1.3.1. Company overview
9.1.3.2. Financial performance
9.1.3.3. Product benchmarking
9.1.3.4. Strategic initiatives
9.1.4. Intellia Therapeutics
9.1.4.1. Company overview
9.1.4.2. Financial performance
9.1.4.3. Product benchmarking
9.1.4.4. Strategic initiatives
9.1.5. Sangamo Therapeutics
9.1.5.1. Company overview
9.1.5.2. Financial performance
9.1.5.3. Product benchmarking
9.1.5.4. Strategic initiatives
9.1.6. Beam Therapeutics
9.1.6.1. Company overview
9.1.6.2. Financial performance
9.1.6.3. Product benchmarking
9.1.6.4. Strategic initiatives
9.1.7. Illumina, Inc.
9.1.7.1. Company overview
9.1.7.2. Financial performance
9.1.7.3. Product benchmarking
9.1.7.4. Strategic initiatives
9.1.8. Editas Medicine
9.1.8.1. Company overview
9.1.8.2. Financial performance
9.1.8.3. Product benchmarking
9.1.8.4. Strategic initiatives
9.1.9. Synthego
9.1.9.1. Company overview
9.1.9.2. Financial performance
9.1.9.3. Product benchmarking
9.1.9.4. Strategic initiatives
Chapter 10. Europe Competitive Landscape
10.1. Company Profiles
10.1.1. Merck KGaA
10.1.1.1. Company overview
10.1.1.2. Financial performance
10.1.1.3. Product benchmarking
10.1.1.4. Strategic initiatives
10.1.2. QIAGEN
10.1.2.1. Company overview
10.1.2.2. Financial performance
10.1.2.3. Product benchmarking
10.1.2.4. Strategic initiatives
10.1.3. Cellectis S.A.
10.1.3.1. Company overview
10.1.3.2. Financial performance
10.1.3.3. Product benchmarking
10.1.3.4. Strategic initiatives
10.1.4. CRISPR Therapeutics
10.1.4.1. Company overview
10.1.4.2. Financial performance
10.1.4.3. Product benchmarking
10.1.4.4. Strategic initiatives
10.1.5. Vivlion GmbH
10.1.5.1. Company overview
10.1.5.2. Financial performance
10.1.5.3. Product benchmarking
10.1.5.4. Strategic initiatives
10.1.6. Eurofins Genomics
10.1.6.1. Company overview
10.1.6.2. Financial performance
10.1.6.3. Product benchmarking
10.1.6.4. Strategic initiatives
10.1.7. AMSBIO
10.1.7.1. Company overview
10.1.7.2. Financial performance
10.1.7.3. Product benchmarking
10.1.7.4. Strategic initiatives
10.1.8. OZ Biosciences
10.1.8.1. Company overview
10.1.8.2. Financial performance
10.1.8.3. Product benchmarking
10.1.8.4. Strategic initiatives
Chapter 11. Asia Pacific Competitive Landscape
11.1. Company Profiles
11.1.1. GenScript
11.1.1.1. Company overview
11.1.1.2. Financial performance
11.1.1.3. Product benchmarking
11.1.1.4. Strategic initiatives
11.1.2. Takara Bio
11.1.2.1. Company overview
11.1.2.2. Financial performance
11.1.2.3. Product benchmarking
11.1.2.4. Strategic initiatives
11.1.3. Macrogen, Inc.
11.1.3.1. Company overview
11.1.3.2. Financial performance
11.1.3.3. Product benchmarking
11.1.3.4. Strategic initiatives
11.1.4. BRL MEDICINE
11.1.4.1. Company overview
11.1.4.2. Financial performance
11.1.4.3. Product benchmarking
11.1.4.4. Strategic initiatives
11.1.5. Biocytogen
11.1.5.1. Company overview
11.1.5.2. Financial performance
11.1.5.3. Product benchmarking
11.1.5.4. Strategic initiatives
11.1.6. BGI Genomics
11.1.6.1. Company overview
11.1.6.2. Financial performance
11.1.6.3. Product benchmarking
11.1.6.4. Strategic initiatives
11.1.7. Bioneer
11.1.7.1. Company overview
11.1.7.2. Financial performance
11.1.7.3. Product benchmarking
11.1.7.4. Strategic initiatives
관련자료
